Vaxcyte Stock Surges Over 25% on Promising Pneumonia Vaccine Trial Results
Vaxcyte shares experienced a significant surge of over 25% following the announcement that its experimental pneumonia vaccine, VAX-31, demonstrated efficacy comparable to existing market vaccines in a large-scale final-stage trial. The vaccine targets 31 strains of bacteria responsible for pneumonia and meningitis.